TSX:GUD - Post Discussion
Post by
Possibleidiot01 on Oct 14, 2023 1:54pm
5i Research
Sep 21, 2023
The share price of GUD has declined over the years, while its fundamentals have been mixed. The company maintains a very strong balance sheet and has grown its top line nicely, but its profits have declined over the years leading to a questionable outlook. GUD has been a disappointment for many, us included. Due to some of its fundamentals maintaining their strength (balance sheet, revenue growth), we have kept it in our coverage list, however, we feel it has been held long enough and with declining margins, we are dropping coverage on Knight Therapeutics (GUD).
Be the first to comment on this post